



GOLD SPONSOR:



SILVER SPONSOR:













WELCOME TO NORDIC PRECISION MEDICINE FORUM 2023

As Precision Medicine initiatives around the world gather pace, the Nordic countries are in an enviable position when it comes to joining all the dots. The link between digital health, omics technologies, artificial intelligence and data means that yet more collaboration is required to ensure the success of precision medicine. As demonstrated by organisations such as SciLifeLab, the collaborative efforts of healthcare, research, industry and patient organisations is really starting to bear fruit.

50+ SPEAKERS INCLUDING:

- **Janne Lehtiö**, PhD Scientific Director, Science for Life Laboratory, Head of Clinical Proteomics Unit, Karolinska Univ. Hospital
- Kristian Hveem, Professor in Medicine and Clinical Epidemiology at the Faculty of Medicine and Health Sciences, the Norwegian University of Science and Technology (NTNU) and senior consultant at St. Olav's University Hospital
- Maxine Mackintosh, Lead of the Diverse Data initiative, Genomics England
- Prof. Dr. Stefan Heinemann, Professor of Business Ethics at the FOM University
 of Applied Sciences and spokesperson of the Ethics Ellipse Smart Hospital at the
 Universitymedicine Essen
- Dan Lasserson is the President of the UK Hospital at Home Society, Professor of Acute Ambulatory Care at the University of Warwick, and the Physician Lead for the Acute Hospital at Home service at Oxford University Hospitals NHS Foundation Trust
- **Nina Linder** is an MD, PhD, and Associate Professor (docent in molecular medicine) at Uppsala University, Sweden and FIMM University of Helsinki
- Dr Graham Belfield, Director of NGS & Transcriptomics within Translational Genomics, AstraZeneca
- **Begonya Nafria Escalera**, Patient Engagement in Research Coordinator at Sant Joan de Déu Chidren's Hospital (Spain)


Key themes for 2023 include:

- Large-scale clinical trials and how these are supporting nextgeneration developments in the Nordics
- Advancing the application of multi-omics from the lab and into practice
- Technology advances in machine learning and AI and how that is advancing Big Data analysis
- Next thinking to take Precision Medicine beyond genomics
- Integrated approaches to delivering the real-world implementation of Precision Medicine in the hospital
- Unblocking data legislation barriers to enablesecondary-use of patient data
- Novel approaches to biomarker discovery






5 REASONS TO JOIN US IN STOCKHOLM 27-28 APRIL 2023



Pick and choose from 35+ sessions and access a wide-range of case studies, research projects, novel applications, policy developments and innovative thinking Access senior influencers, project leaders and change-makers from across the region – all in one place – for a networking and collaboration opportunity like no other Share your insights and be part of the conversation through panel discussions, Q&A sessions and small-group discussions throughout the programme



Put your questions to 40+top experts from across the Nordics ranging from government, industry, technology, research and healthcare Whatever your contribution to advancing Precision Medicine, walk away with new ideas and connections to inspire your next project, solve critical challenges and be a part of shaping the future



The three different events will run in parallel so please check out further pages for the other agendas.

Registration and Networking Coffee

Opening remarks from Chair

Bettina Lundgren, CEO, Danish National Genome Center

Opening Plenary

Nordic Precision Medicine Update

Genomic Medicine Sweden - current status and future directions

- Summarising the current status of Genomic Medicine Sweden in implementing precision medicine across the country.
- Discussing future directions in terms of implementing new technologies and involving new disease areas.

Richard Rosenquist Brandell, Director, Genomic Medicine Sweden

An update from the Danish National Genome Center

- Patients in focus a national strategy of personalised medicine in Denmark
- NGC's core output: Support personalised medicine and implementation in the healthcare system and research
- Future developments of personalised medicine in Denmark

Bettina Lundgren, CEO, Danish National Genome Center

The New Norwegian Strategy for Personalised Medicine

- What direction will the Norwegian Government take?
- What is the vision for Precision Medicine?
- What are the main strategic areas and some of the actions that will be undertaken?

Nils Olav Refsdal, Norwegian Ministry of Health

Finland: The Current Status of Genomic Medicine and the **Progress of the National Genome Strategy**

- Large Genome Activities in Finland
- Finnish National Genome Strategy
- Genomic data kick starts precision medicine in Finland

Markus Perola, Research Professor at Finnish Institute for Health and Welfare

Refreshments and Networking

11.30

Development of the Norwegian Precision Cancer Medicine implementation initiative - A status report

- Screening and recruitment
- Aggregated interim results across cohorts in the trial
- **Key learnings**
- Way forward

Kjetil Tasken, Head and Director of Institute of Cancer Research at Oslo University Hospital and Professor at University of Oslo

Sponsor Presentation

Development and implementation of precision medicine from an industry perspective

- Development of precision medicine from an industry perspective
- Implementation of precision medicine the way forward
- A precision based health care system how can industry contribute and development

Frida Lundmark, Expert in Life Science, research & innovation

12.30 Lunch

13,45

WORKSHOPS:

Choose to join one of the workshops to deep-delve on a particular topic

Topics include:

Polygenic Risk Scoring - PRS as a tool for prediction and early prevention of diseases Clinical implementation of precision

Clinical Implementation of Precision Medicine examples of PM in the clinic, how do best make PM ubiquitous across healthcare

14.45

From population studies to clinical application - a precision medicine perspective

Kristian Hveem, Professor in Clinical Epidemiology and Medicine, Norwegian University of Science and Technology (NTNU)

15.05 TBC

15.30

Refreshments and Networking



16.00 Nordic collaboration between trials **Panel Discussion**

Katriina Peltola Head Physician, Associate Professor HUS Comprehensive Cancer Center, Clinical Trial Unit

Kjetil Tasken, Head and Director of Institute of Cancer Research at Oslo University Hospital and Professor at University of Oslo

Hans Gelderblom, Chair of the Department of Medical Oncology Leiden University Medical Center

Peter Asplund, Project Director, MEGALiT

Kristoffer Rohrberg, Head of the Phase 1 Unit, Rigshospitalet

17.15 **Networking drinks reception**



DAY 2 - FRIDAY 28 APRIL 2023

09.00

Opening remarks from Chair

Bettina Lundgren, CEO, Danish National Genome Center

09.10

Paediatric centric clinical trials: a right for children and young people

- Children's rights in their involvement in clinical research
- Why? Who? Where? Involve children and young people
- Return on the investment and return on the engagement
- eYPAGnet: European Network of Young Person's Advisory Groups Network

Begoña Nafría Escalera, Patient Engagement in Research Coordinator, Hospital Sant Joan de Déu

09.30

The increasing importance of the role of the patient from early research to the clinic

Patient Representative TBC

09.50

Panel discussion

Patient involvement in Precision Medicine – from early research to the clinic

Begoña Nafría Escalera, Patient Engagement in Research Coordinator, Hospital Sant Joan de Déu

Patient Representative TBC

10.20

EATRIS, the European Infrastructure for translational medicine. A multinational approach for the progress of Precision Medicine

- Distributed research infrastructures as a key asset for the progress of Precision medicine.
- The translational medicine paradigm for transforming the scientific knowledge into a real patient-tailored health care intervention
- Moving from the genomic medicine domain to the precision medicine domain.
- The EATRIS multiomic toolbox.

Toni Andreu, Scientific Director, EATRIS

10.40

Refreshments and Networking

11.15

- The globalisation of precision healthcare
- Why context matters when developing precision health solutions

- Transferability of precision healthcare solutions from European-ancestry populations to others
- The challenge of data availability outside Europeanancestry populations

Paul Franks, Professor & Head of Translational Medicine at Novo Nordisk Foundation

11.35

Multi Omics Session

Multi-omics is allowing scientists to probe the more complex and transient molecular changes that underpin the course of disease and response to treatment. This Session brings together a group of experts with background across metabolomics, proteomics, transcriptomics and genomics to debate how best we can integrate these technologies to generate predictive scientific outcomes with greater certainty.

Building on the Solid Foundations of Genomics *Craig Wheelock, Associate Professor, Karolinska Institute*

The evolving role of Transcriptomics in Drug-discovery

- A Historical perspective on Transcriptomics
- · What questions can we answer
- What do we measure and how
- How will the data be used
- Multiomics future perspective

Graham Belfield, Director NGS/Transcriptomics -Translational Genomics at AstraZeneca

Title TBC

Michael Wierer, Director, Proteomics Research Infrastructure (PRI)

12.35

Lunch

13.50

Precision medicine beyond oncology Panel discussion Ditte Demontis, Professor, Dept of Biomedicine, Aarhus University – Title TBC

14.50

Collaboration as a key drive to achieve the promise of Precision Medicine

Our panel made up of industry, research, healthcare and patient representatives describe how we can bets fulfil the promise of precision medicine

15.50

Closing remarks

16.00

Close



Registration and Networking Coffee

09.45

Opening remarks from Chair Bettina Lundgren, CEO, Danish National Genome Center

09.50 **Opening Plenary**

Nordic Precision Medicine Update

Genomic Medicine Sweden – current status and future directions

- Summarising the current status of Genomic Medicine Sweden in implementing precision medicine across
- Discussing future directions in terms of implementing new technologies and involving new disease areas.

Richard Rosenquist Brandell, Director, Genomic Medicine Sweden

An update from the Danish National Genome Center

- Patients in focus a national strategy of personalised medicine in Denmark
- NGC's core output: Support personalised medicine and implementation in the healthcare system and research
- Future developments of personalised medicine in Denmark

Bettina Lundgren, CEO, Danish National Genome Center

The New Norwegian Strategy for Personalised Medicine

- What direction will the Norwegian Government take?
- What is the vision for Precision Medicine?
- What are the main strategic areas and some of the actions that will be undertaken?

Nils Olav Refsdal, Norwegian Ministry of Health

Finland: The Current Status of Genomic Medicine and the **Progress of the National Genome Strategy**

- Large Genome Activities in Finland
- Finnish National Genome Strategy
- Genomic data kick starts precision medicine in Finland

Markus Perola, Research Professor at Finnish Institute for **Health and Welfare**

11.00

Refreshments and Networking

11.30

Making precision medicine work

- Molecules are not sufficient to produce better health outcomes
- Precision medicine is not the same as personalised care but both are interdependent
- Outcomes are dependent on a range of improvements along the care process
- Affordability is not only dependent on the costeffectiveness of a single diagnostic or pharmaceutical

Nick Guldemond, Professor Healthcare and Public Health, Leiden University Medical Center

12.00

- Deep learning based AI for human expert level diagnostics (and beyond)
- Development of deep learning based AI for digital pathology
- Crowdsourcing based development of AI for solving realworld problems in pathology
- Enabling staining-free histopathology through Al-based virtual staining

Pekka Ruusuvuori, Assistant Professor, University of Turku

12.25 Lunch

13.45

Artificial intelligence for digital diagnostics at the point-of care

- Point of care diagnostics using artificial intelligence
- Cervical cancer screening in Kenya using Al
- Pros, cons and ethics using the described approach

Nina Linder, Senior Scientist, FIMM



14.10

How do I turn this on? What to consider when adopting AI-based tools into clinical practice

Artificial intelligence (AI) has great potential to transform healthcare, making it more efficient, equitable, and safe. Despite interest from both clinicians and management, the adoption of Al-based tools in healthcare settings are still limited due to numerous hurdles. In this talk, we provide an overview of these hurdles and suggest considerations based on our findings from synthesising the literature, as well as from interviews and a workshop with stakeholders who have experience with this Al adoption process. The considerations are targeted towards the adopters of AI, such as healthcare administrators and management, clinical and non-clinical healthcare staff, and researchers.

Harry Hallock, Senior Researcher - Group Research and Development, DNV

14.35

The Danish National Biobank, data and lessons learned from COVID 19

Henrik Ullum, Chief Executive Officer, Statens Serum Institut

15.00

Technology Presentation

15.25

Refreshments and Networking

16.00

Combination Markers for Combination Treatments Janne Lehtio, Professor, Karolinska Institutet

16.30

Enabling Safe, Secure data Sharing

16.55

TBC

17.15

Networking Drinks Reception



DAY 2 - FRIDAY 28 APRIL 2023

09.00

How Data Science Can Improve Equity in Genomics and Health

Data and digital technology are now being used in all aspects of research, innovation and healthcare, but how do we ensure that the entire healthcare system benefits from these advanced technologies, specifically so that all people, especially those in underserved populations, receive the same quality of research benefit and care from innovations? This talk will discuss the intersection of data science, health and equity, illustrated by the inequities rife in genomics.

Maxine Mackintosh, Programme Lead on Diverse Data, Genomics England

09.25

Artificial Intelligence in Drug Discovery 2023 – Aspects of Data, Validation and Translation

Artificial Intelligence has made great progress in areas such as image and speech recognition. In this contribution we will review what is different when applying Al in the drug discovery field. A focus will be on the current state of affairs, as well as aspects of data, model validation, and clinical translation.

Andreas Bender, Professor for Molecular Informatics, University of Cambridge

09.50

Technology Presentation

10.15

Panel Discussion

10.40

Refreshments and Networking

11.15

Workshops

12.30

Networking Lunch

13.50

Peter Coveney, Associate Director, Advanced Research Computing Centre (ARC), University College London – title TBC

14.15

Translating AI research into clinical practice

14.40

Title TBC

- State of Al in Swedish healthcare, what are the s tatus, challenges
- Accelerate applied AI in healthcare through collaboration
- Examples from a few applied AI projects in healthcare

Johanna Bergman, Head of Strategic Initiatives, AI Sweden

15.15

TEF Health

A major project to promote the rapid introduction of new artificial intelligence (Al) and robotics solutions in healthcare

16.00

Close



11.30

Opening Remarks

11.35am

How to use data to create more value in healthcare with a clear clinical focus, and using modern, digital technology

How is Microsoft's role as an enabler developing healthcare and being more connected, person cantered, and proactive? Clinical use cases created by Microsoft, customers, and partners Nasim Bergman Farrokhnia, Industry Advisor, Healthcare Executive (Western Europe), Microsoft

12.00

The Swedish eHealth Agency and digital health Where are we with

- The Vision for eHealth2025
- The European Health Data Space

Maria Bäcklund-Hassel, Senior Advisor and International Coordinator, The Swedish eHealth Agency

12.25

Networking Lunch

13.45

Show me the evidence... I'll wait

- Overview of the promises/opportunity of digital health innovation [some of the big claims]
- A summary of the state of the evidence in the field for much of what we use
- A brief look back at history to see what happens when we make decisions based on "biological plausibility", "intermediate outcomes", and "logic"
- A call to action around needing more best-in-class evidence for digital health, in an effort to support policy and decision makers

Bilal Mateen, Senior Manager (Digital Technology), Wellcome Trust

14.10

POINT OF CARE DIAGNOSTICS AND CARE PATHWAY PRECISION IN ACUTE HOSPITAL AT HOME

- Point of care blood testing and ultrasound imaging can be used in the home and care home setting
- Availability of a broad range of POC diagnostics can support acute medical care decision making and treatmentoutside the acute hospital
- Cloud based image sharing and real time uploads of blood tests enable specialist and generalist collaboration in the care of complex patients with multimorbidity and frailty

Daniel Lasserson, Professor of Acute Ambulatory Care, University of Warwick. Clinical Lead - Acute Hospital at Home, Oxford University Hospitals NHS Foundation Trust. President, UK Hospital at Home Society

14.35

Georgi Natchev, CEO, Digiburn – title TBC

15.00

Technology Presentation

15.25

Refreshments and Networking

16.00

Jerome de Barros, Policy Officer – Digital Health, European Commission – title TBC

16.30

Driving progress in digital mental health

- Wellcome's Strategy on Mental Health (with focus on digital mental health)
- Current challenges in digital mental health research
- Update on regulatory challenges in digital mental health and Wellcome's investments in this field.

Elena Netsi, Senior Portfolio Manager, Mental Health Translation, Wellcome Trust

16.55

Technology Focus

17.15

Networking Drinks Reception



DAY 2 - FRIDAY 28 APRIL 2023

11.15 Workshops

12.30 **Networking Lunch**

13.50

Start Up sessions:

With the buzz around digital health, Al and precision medicine there are a whole plethora of Start-ups, university spin outs and SME's offering solutions. This session provides an opportunity for these innovative companies to share their products and services with the audience via elevator pitch sessions and interactive Q&A. A great chance to see new developments from cutting edge researchers and budding entrepreneurs who will shape the future.

16.00 Close The lines between the different disciplines involved in precision medicine are often blurred, so to bring all of the people together we have created three unique meetings which allow our attendees to move freely between different areas of interest. Through a combination of keynotes, presentations, panel discussions, breakouts and networking opportunities, you will have access to those who are shaping the digital health revolutions across the region, under one roof, over two days.

SPONSORSHIP OPPORTUNITIES

Nordic Precision Medicine Forum offers a unique environment to make new connections, share ideas and formulate partnerships for future collaboration. We work closely with our sponsors to ensure that your objectives are met by building bespoke marketing solutions. So be it a plenary speaking slot, hosting a roundtable or exhibiting at our forum, we ensure you are in front of the right audience.

For more information please contact **Steve Coldicott** stevecoldicott@precisionmedicineforum.com

INTERESTED IN SUBMITTING A POSTER FOR THE FORUM?

- Submit an abstract by Friday 31st March 2023 to *liz@precisionmedicineforum.com*
 - The acceptable word range for the abstract is 175 275 words.
 - Your submission should be in English
- Please email in a brief biography together with the abstract as a word or pdf document
 - Posters will then be chosen from all abstracts submitted by the abstract deadline
- If selected, you will be expected to present your poster in person at the Nordic Forum

